Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1

Status

Completed 2Terminated 1

Sponsor Class

OTHER 44INDUSTRY 8NIH 4NETWORK 3

Study Type

Interventional 3

Sponsor

Cancer Type

Sarcoma 1Genitourinary 1Dermatologic 1

Conditions

Osteosarcoma 1Melanoma 1Kidney Neoplasms 1Carcinoma, Renal Cell 1

Interventions

Radiotherapy 299Cisplatin 263Cyclophosphamide 229Doxorubicin 176Paclitaxel 167Vincristine 160Carboplatin 150Filgrastim 139Etoposide 139Gemcitabine 118Fluorouracil 113Docetaxel 112Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 91Leucovorin 90Granulocyte Colony-Stimulating Factor 74Specimen Handling 66Magnetic Resonance Spectroscopy 62Capecitabine 59Irinotecan 58Radiation 54Ifosfamide 51Oxaliplatin 48Daunorubicin 48Temozolomide 47Radiotherapy, Conformal 47Platinum 47Peripheral Blood Stem Cell Transplantation 47

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
NETWORK × Interventional × peginterferon alfa-2b × Clear all
NCT00049530 2023-06-29

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Eastern Cooperative Oncology Group

Phase 2 Completed
32 enrolled 8 charts
Dermatologic

Melanoma

NCT00134030 2023-06-07

EURAMOS-1

Children's Oncology Group

Phase 3 Completed
1,334 enrolled 17 charts
Sarcoma

Osteosarcoma

NCT00467077 2017-03-17

Gefitinib and PEG-Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer

California Cancer Consortium

Phase 2 Terminated
21 enrolled 8 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡